X4 Pharmaceuticals, Inc (XFOR) Stock Price & Analysis
X4 Pharmaceuticals, Inc (XFOR) rose 3.77% to USD 3.85 as of June 10, 2026 at 07:07 UTC, according to Nexqual real-time market data.
XFOR last closed at USD 3.71; the session ranged USD 3.71–3.95 on volume of 433,778 shares. Market capitalization is $363.13M, with a 52-week range of USD 1.35–4.83 (NCM). Source: Nexqual, June 10, 2026 at 07:07 UTC.
Key Statistics (as of June 10, 2026 at 07:07 UTC)
| Price | USD 3.85 |
|---|---|
| Change | ▲ 3.77% (up) |
| Previous Close | USD 3.71 |
| Open | USD 3.71 |
| Day Range | USD 3.71 – 3.95 |
| 52-Week Range | USD 1.35 – 4.83 |
| Volume | 433,778 shares |
| Market Cap | $363.13M |
| Exchange | NCM |
Technical Analysis (XFOR)
Nexqual's technical model rates XFOR "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.02 (neutral) |
| vs SMA50 | Below (USD 4.11) |
| MACD | -0.06 (negative) |
Analyst Ratings (XFOR)
Wall Street analysts rate XFOR "Strong Buy" based on 4 analysts, with a mean price target of USD 11.75 (range USD 10–13), per Nexqual as of June 10, 2026 at 07:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 11.75 |
| High Target | USD 13 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (XFOR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $2.27M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.16 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.22 vs est -0.35 ▲ beat |
| 2025-09-30 | USD -0.69 vs est -0.84 ▲ beat |
| 2025-06-30 | USD -3.47 vs est -4.34 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:07 UTC.
Financials & Fundamentals (XFOR)
| Total Revenue | $9.01M |
|---|---|
| Revenue Growth (YoY) | -90.60% |
| Gross Margin | +81.82% |
| Operating Margin | -748.49% |
| Profit Margin | +0.00% |
| ROE | -104.21% |
| Debt / Equity | 45.86 |
| Current Ratio | 10.18 |
| Total Cash | $233.72M |
| Total Debt | $77.25M |
| Free Cash Flow | $-55.17M |
Source: Nexqual, June 10, 2026 at 07:07 UTC.
Financial Health Score (XFOR)
Nexqual rates X4 Pharmaceuticals, Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $234M cash vs $77M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$55M, burning cash |
| Efficiency | Critical — ROE -104%, ROA -28.3% |
Ownership (XFOR)
| Insider Ownership | +0.54% |
|---|---|
| Institutional Ownership | +99.60% |
| Shares Outstanding | 94.32M |
| Float | 57.41M |
| Short % of Float | +3.58% |
Source: Nexqual, June 10, 2026 at 07:07 UTC.
Leadership (XFOR)
X4 Pharmaceuticals, Inc is led by John P. Volpone (age 50), President & COO, per Nexqual as of June 10, 2026 at 07:07 UTC.
| President & COO | John P. Volpone (age 50) |
|---|---|
| CFO, Treasurer & Corporate Secretary | David H. Kirske (age 71) |
Major Backers & Investors (XFOR)
Notable institutional backers of X4 Pharmaceuticals, Inc include Morgan Stanley, Empery Asset Management, LP, Fidelity, according to Nexqual as of June 10, 2026 at 07:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 12.51% |
| Empery Asset Management, LP | 9.48% |
| Fidelity | 8.93% |
| FMR, LLC | 8.59% |
| Bain Capital Life Sciences Investors, LLC | 8.45% |
| Perceptive Advisors Llc | 7.14% |
| Saturn V Capital Management LP | 6.85% |
| Deep Track Capital, Lp | 6.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.33% |
Source: Nexqual, June 10, 2026 at 07:07 UTC.
From X4 Pharmaceuticals, Inc's Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
- It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
- It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OVID | Ovid Therapeutics Inc. | USD 2.42 | ▲ 0.83% |
| PDSB | PDS Biotechnology Corporation | USD 1.03 | ▲ 0.98% |
| TRVI | Trevi Therapeutics, Inc. | USD 13.59 | ▲ 1.95% |
| MREO | Mereo BioPharma Group plc | USD 0.31 | ▼ 2.24% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 6.12 | ▲ 1.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:07 UTC. This page is informational and not investment advice.